Oct 20, 6:00 AM ET
Northrop Grumman reported third quarter 2026 sales of $11.1 billion, up 7% from $10.4 billion a year earlier, and diluted earnings per share of $7.89 versus $7.67. The company raised its 2026 guidance for sales, segment operating income and MTM-adjusted EPS, while operating margin rate declined to 11.4% from 11.9%.
- Q3 2026 sales rose 7% to $11.1 billion; net earnings were $1.1 billion, or $7.89 per diluted share, versus $7.67 a year earlier
- 2026 MTM-adjusted EPS guidance raised to $29.35 to $29.75 from $28.60 to $29.10; sales guidance is $43.75 billion to $44.25 billion
- Backlog reached $109.6 billion at September 30, 2026, up 15% from $95.7 billion at December 31, 2025; net awards were $16.4 billion in the quarter
Read the filing on SEC.gov ↗
Aug 21, 5:06 PM ET
Northrop Grumman's independent directors approved a one-time performance-based equity grant to Chair, CEO and President Kathy J. Warden on August 19, 2026. The award pays out based on the company's absolute stock price change through December 31, 2031, and is tied to her continued service, which links her pay directly to shareholder returns.
- Award approved by independent directors on August 19, 2026; disclosed in an 8-K dated August 21, 2026
- Target award is 35,910 Market Stock Units (MSUs), with payout ranging from 0% to 150% of target
- Performance period ends December 31, 2031; full target payout requires at least 10% stock price appreciation
- Payout is 0% if the stock falls more than 25% and 150% if it rises 50% or more
Read the filing on SEC.gov ↗
Jul 21, 6:45 AM ET
Northrop Grumman reported second quarter 2026 sales of $10.9 billion, up 5% from a year earlier, and a record backlog of $105 billion. Diluted EPS fell to $7.68 from $8.15 because the prior-year quarter included a $231 million gain on the training services divestiture, and the company raised its 2026 sales and MTM-adjusted EPS guidance.
- Q2 2026 sales were $10.9 billion, up 5% from $10.4 billion in Q2 2025.
- Diluted EPS was $7.68 versus $8.15; net earnings were $1.1 billion versus $1.2 billion.
- 2026 sales guidance raised to $43.75 billion to $44.25 billion; MTM-adjusted EPS guidance raised to $28.60 to $29.10, an increase of $1.20.
- Backlog reached a company record of $105 billion after $20 billion in net awards in the quarter.
Read the filing on SEC.gov ↗
Apr 21, 6:44 AM ET
Northrop Grumman reported first-quarter 2026 sales of $9.9 billion, up 4% from $9.5 billion a year earlier, and diluted earnings per share of $6.14 versus $3.32. The gain was largely due to the absence of a $477 million B-21 loss provision recorded in the prior-year quarter, and the company reaffirmed its 2026 financial guidance. Shareholders get a clear improvement in the headline measures, though first-quarter free cash flow was negative $1.8 billion.
- Sales rose 4% to $9.9 billion; organic sales rose 5% to $9.9 billion from $9.4 billion
- Diluted EPS was $6.14 versus $3.32; net earnings were $875 million versus $481 million
- Operating margin rate was 10.0% versus 6.1%, driven by the absence of the prior-year $477 million B-21 loss provision
- 2026 guidance reaffirmed as of April 21, 2026: sales $43.5 billion to $44.0 billion and MTM-adjusted EPS $27.40 to $27.90
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.